11βHSD1 deficiency or inhibition enhances hepatic myofibroblast activation in murine liver fibrosis by Zou, X et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11HSD1 deficiency or inhibition enhances hepatic myofibroblast
activation in murine liver fibrosis
Citation for published version:
Zou, X, Ramachandran, P, Kendall, T, Pellicoro, A, Dora, E, Aucott, R, Manwani, K, Man, T, Chapman, K,
Henderson, N, Forbes, S, Webster, S, Iredale, J, Walker, B & Michailidou, Z 2017, '11HSD1 deficiency or
inhibition enhances hepatic myofibroblast activation in murine liver fibrosis', Hepatology.
https://doi.org/10.1002/hep.29734
Digital Object Identifier (DOI):
10.1002/hep.29734
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Hepatology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
 11βHSD1 deficiency or inhibition enhances hepatic myofibroblast 
activation in murine liver fibrosis. 
Zou X
1,2,4
, Ramachandran P
2,4
, Kendall TJ
2
, Pellicoro A
2
, Dora E
2
, Aucott RL
2
 , Manwani 
K
1
, Man TY
1
, Chapman KE
1
, Henderson NC
2
, Forbes SJ
3
, Webster SP
1
, Iredale JP
2
, Walker 
BR
1
, Michailidou Z
1,2*
 
Author Affiliations: 
1
 The University of Edinburgh /BHF Centre for Cardiovascular Science; 
2
 The University of Edinburgh/ MRC Centre for Inflammation Research, 
3
 The University of 
Edinburgh/MRC Centre for Regenerative Medicine, Queen's Medical Research Institute, 47 
Little France Crescent, Edinburgh EH16 4TJ, UK.
4
 these authors contributed equally. 
*Corresponding Author: Zoi Michailidou, v1zmicha@staffmail.ed.ac.uk  
Key words: glucocorticoids, macrophages, collagen, carbon tetrachloride  
List of Abbreviations. 
ALT alanine aminotransferase 
AST aspartate aminotransferase 
GC glucocorticoids 
11βHSD1 11beta-hydroxysteroid dehydrogenase-1 
HSC hepatic stellate cells 
MFB hepatic myofibroblasts 
NASH: Non-alcoholic steatohepatitis 
Financial Support. This work was funded by the British Heart Foundation (BRW), a Henry 
Wellcome Postdoctoral Fellowship (ZM; 085458/Z/08/Z) and a British Heart 
Foundation/University of Edinburgh Centre of Research Excellence Transition Award 
Fellowship (ZM). Mice were generated under a Wellcome Trust Programme Grant  
08318/4/Z/07/Z (to JR Seckl, JS Savill, KE Chapman, JJ Mullins and BRW). UE2316 was 
This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process which may lead to
differences between this version and the Version of Record. Please cite this article as
doi: 10.1002/hep.29734
This article is protected by copyright. All rights reserved.
2 
 
generated with a Wellcome Trust Seeding Drug Discovery award (SPW and BRW). Xiantong 
Zou was supported by the Chinese Scholarship Council.  
2-sentence Summary of Manuscript:  
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Abstract 
A hallmark of chronic liver injury is fibrosis, with accumulation of extracellular matrix 
orchestrated by activated hepatic stellate cells (HSCs). Glucocorticoids (GC) limit HSC 
activation in vitro and tissue GC levels are amplified by 11beta-hydroxysteroid 
dehydrogenase-1 (11βHSD1). Although 11βHSD1 inhibitors have been developed for type 2 
diabetes mellitus and improve diet-induced fatty liver in various mouse models, effects on the 
progression and/or resolution of liver injury and consequent fibrosis have not been 
characterised.  Here we have used the reversible carbon tetrachloride-induced model of 
hepatocyte injury and liver fibrosis to show that in 2 models of genetic 11βHSD1 deficiency 
(global; Hsd11b1
-/-
 and hepatic myofibloblast-specific; Hsd11b1
fl/fl
 /Pdgfrb-cre) and 
11βHSD1  pharmacological inhibition in vivo exacerbates hepatic myofibroblast (MFB) 
activation and liver fibrosis. In contrast, liver injury and fibrosis in hepatocyte-specific 
Hsd11b1
fl/fl
/albumin-cre mice did not differ from that of controls, ruling out 11βHSD1 
deficiency in hepatocytes as the cause of the increased fibrosis. In primary hepatic stellate 
cell (HSC) culture, glucocorticoids inhibited expression of the key profibrotic genes Acta2 
and Col1α1, an effect attenuated by the 11βHSD1 inhibitor UE2316.  HSCs from Hsd11b1
-/- 
 
and  Hsd11b1
fl/fl
 /Pdgfrb-cre mice expressed higher levels of Acta2 and Col1α1 and were 
correspondingly more potently activated. In vivo UE2316 administration prior to chemical 
injury recapitulated findings in Hsd11b1
-/-
 mice, including greater fibrosis. Conclusion: 
11βHSD1 deficiency enhances MFB activation and promotes initial fibrosis following 
chemical liver injury. Hence, the effects of 11βHSD1 inhibitors on liver injury and repair are 
likely to be context-dependent and deserve careful scrutiny as these compounds are 
developed for chronic diseases including metabolic syndrome and dementia.  
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The prevalence of chronic liver disease is increasing globally. Regardless of the underlying 
cause, alcohol, metabolic disease or non-alcoholic steatohepatitis (NASH), hepatic damage 
results in fibrosis-  a dynamic process characterized by accumulation of extracellular matrix 
(1). Activated hepatic stellate cell/ myofibroblasts (HSC/MFB) are the major source of 
extracellular matrix in mouse liver fibrosis models (1-2), while scar associated macrophages 
facilitate the spontaneous resolution of liver fibrosis (3). The severity of fibrosis, for example 
in NASH patients, is correlated with adverse clinical outcomes (4-5). Currently there is no 
effective regime to limit fibrosis without adversely affecting repair (4), therefore, novel 
disease-modifying anti-fibrotic therapies are needed.  
 
Glucocorticoids have wide ranging actions that modulate many of the pathological processes 
that occur during tissue injury and repair and which contribute to liver fibrosis (6). Tissue 
glucocorticoid levels are regulated by the intracellular enzyme 11βHSD1 that converts 
inactive cortisone into active cortisol in humans (or 11dehydro-corticosterone into 
corticosterone in mice) and is highly abundant in liver (7).  11βHSD1 influences hepatic lipid 
accumulation, with transgenic 11βHSD1 overexpression in liver leading to hepatic steatosis 
and dyslipidemia while 11βHSD1 deficiency protects from hepatic steatosis on a high fat diet 
(8-9). However, little is known of the role of 11βHSD1 in liver fibrosis. One observational 
study showed no association between liver 11βHSD1 expression and the pathology of fatty 
liver or NASH in humans (10). In contrast, another study showed that in early stages of 
NAFLD, with steatosis alone, hepatic 11βHSD1 activity is reduced whereas progression to 
NASH was associated with increased 11βHSD1 levels (11).  
 
Importantly, 11βHSD1 inhibitors have been developed and shown to be moderately 
efficacious in Phase 2 clinical trials in patients with type 2 diabetes (12). Moreover, a recent 
study showed that administration of the 11βHSD1 inhibitor RO5093151 in NAFLD patients 
reduced liver lipid content (13). Given the potential use of 11βHSD1 inhibitors as a therapy 
in patients either at risk of NAFLD or with established hepatic steatosis, it is imperative to 
understand the influence of 11βHSD1 on liver fibrosis.  
In this study, we sought to define the direct effects of limiting liver glucocorticoid availability 
on hepatic fibrosis, independent of metabolic functions. We therefore, utilized global, 
hepatocyte-specific and stellate/myofibroblast-specific 11βHSD1 deficient mice and a 
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specific small molecule 11βHSD1 inhibitor, to study the functional role of 11βHSD1 in 
murine models of toxin-induced liver fibrosis. We demonstrate, for the first time, that 
11βHSD1 deficiency or inhibition promotes MFB activation and liver fibrogenesis in the 
CCl4 model.  
 
Materials and Methods  
Mouse liver fibrosis models. All experiments involving animals were approved by The 
University of Edinburgh Animal Welfare and Ethical Review Body and by the United 
Kingdom Home Office. Experiments used adult male (14 weeks of age) mice with global 
deficiency (Hsd11b1
−/−
; GKO) (14).  The GKO mice have been backcrossed for over 10 
generations on a C57Bl/6J genetic background and C57Bl/6J mice were used as controls (15-
18).  GKO were maintained in parallel with the control C57Bl/6J; both lines were bred and 
maintained within our biomedical research facility housed under standard conditions. To 
avoid inter-animal variability that would be introduced due to differences in the stage of 
estrous in females, only male mice were used. Male mice (12 weeks of age) in which deletion 
was targeted to hepatocytes (LKO) were generated by crossing Albumin-Cre
Tg/+ 
mice (B6.Cg-
Tg(Alb-cre)21Mgn/J; Jackson Laboratories) with mice homozygous for a “floxed” allele of 
Hsd11b1 (Hsd11b1
fl//fl
) in which exon 3 is flanked by LoxP sites (generated by Artemis 
Pharmaceuticals directly onto a C57BL/6 background and designated Hsd11b1
tm1Arte
, MGI 
5784734). Cre-mediated excision of exon 3 generates a null allele (19). Cre
-
 Hsd11b1
fl//fl
 
littermates served as controls for LKO mice. To target deletion specifically at  
myofibroblast/stellate cells (MFKD) , Hsd11b1
fl//fl 
mice were crossed with the platelet-
derived growth factor receptor beta (Pdgfrb)-Cre
Tg/+  
mice (20). Cre
-
 Hsd11b1
fl//fl
 littermates 
served as controls for MFKD mice. 
 
Carbon tetrachloride (CCl4) model. Mouse chronic liver fibrosis was induced by i.p. 
injection of 25% CCl4/g twice weekly for 12 weeks. Male GKO or LKO and their control 
littermates were culled at 24 hours (peak fibrosis), 72 hours, 1 week and 1 month (scar 
resolution phases) after the last injection, as previously validated (3). MFKD male mice were 
culled 24h after the last CCl4 injection to evaluate the role of 11βHSD1 deficiency at the 
peak fibrotic response.  For acute injury, a single dose of 25% CCl4 / g  ip was given in GKO 
or control mice and livers and plasma were  collected after 24h.   
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In male C57Bl/6J mice, pharmacological 11βHSD1 inhibition was achieved by mixing chow 
diet with 0.15% UE2316 ([4-(2-chlorophenyl-4-fluoro-1-piperidinyl][5-(1H-pyrazol-4-yl)-3-
thienyl]-methanone). Groups of C57Bl6/J mice were given either a chow diet (CD) or diet 
containing UE2316 (UE) ad libitum (21) either throughout 12 weeks of CCl4 administration 
and until sacrifice, or only from 48h after the last CCl4 injection until sacrifice, ie during 
resolution (UE-R). Mice were sacrificed at 6 hours, 24 hours, 72 hours and 8 days after the 
last CCl4 injection.  
 
Alternative liver pathology models. An alternative model of liver fibrosis was induced in 
C57Bl/6J mice by administration of thioacetamide (TAA; 600 mg/L) in drinking water for 1 
year. Livers were harvested 24 hours or 1 week after TAA termination. To induce steatosis 
and NASH in a model of NAFLD, GKO male mice and age-matched C57Bl/6J mice aged 6-
10 months were fed commercially available diets (all from Dyets, Bethlehem, PA, US): 
control (Con, 518574), choline deficient (CDD, 518753) or methionine-choline deficient 
(MCDD, 518810), for 2 weeks as previously described (22). 
 
Isolation of non-parenchymal liver cells and flow cytometry. Fresh liver was perfused with 
5 ml saline via the portal vein and 100-300 mg then digested with RPMI1640 medium with 
Dnase I and Collagenase IV at 37
o
C. After digestion, hepatocytes were pelleted and discarded 
by centrifugation at 50g for 5 minutes. Non-parenchymal cells were washed with RPMI 1640 
medium and pelleted by centrifugation at 350g for 15 minutes, then washed and blocked with 
10% mouse serum for 30 minutes. Antibodies against CD11b (clone M1/70; Ebioscience, 
Hatfield, UK), Ly-6C (clone HK1.4; Ebioscience), CD45.2 (clone 104; Ebioscience), F4/80 
(dilution 1:50; clone BM8; Invitrogen), Ly-6G (clone 1A8; Biolegend, San Diego, CA,US) 
were added for 30 minutes, in a dilution of 1:100 unless specified.  Cell viability was 
assessed with Fixable Viability Dye eFluor780 (Ebioscience) according to the manufacturer’s 
protocols. Cells were formalin fixed and analysed by flow cytometry using a BD LSR 
Fortessa II (BD Bioscience, Oxford, UK).  
 
Immunofluorescence and immunochemistry. For immunohistochemistry, livers were fixed 
with formalin for 16 hours directly after harvest. 4µm sections were de-waxed and rehydrated 
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followed by antigen retrieval in boiling sodium citrate. Avidin and Biotin were blocked 
according to the manufacturer’s protocol (Vector, Peterborough, UK). Protein block (DAKO, 
Cambridge, UK) or serum was added and sections were then incubated with αSMA (Sigma 
Aldrich, Dorset, UK) or collagen I or GR1(Ly6G) (Cambridge bioscience, Cambridge, UK) 
or F4/80 (Abcam, Cambridge, UK) or Reelin (Abcam, Cambridge, UK)  antibodies at 4
o
C 
overnight and subsequent secondary antibody for 30 minutes. After ABC vector incubation, 
the sections were incubated with DAB for 10 minutes, counter stained with haematoxylin. 
Picrosirius red staining (PSR) was performed as previously described (3,23) . 30–40 high 
power fields (magnification ×80) per section were randomly selected for each slide by an 
assessor blind to genotype. Images were analysed in Photoshop CS3 for positive stained 
pixels and normalized to total number of pixels. In the Period Acid-Schiff  (PAS) stain, 
necrotic cell area was quantified in a blinded manner using Image J Trainable Weka 
Segmentation tool.  
 
Liver Histopathology. Blinded hematoxylin and eosin (H&E) stained sections from the acute 
single dose CCl4 and the chronic CCl4 injury models (at 24h peak fibrosis) were evaluated 
by a pathologist using 2 separate ordinal scales.; Inflammation was scored using the  
inflammation component of the NAS scoring system for NASH  (24) (0 – no inflammation; 1 
- <2 necroinflammaoty foci/20x field; 2 – 2-4 necroinflammatory foci/20x field; 3 - >4 
necroinflammatory foci/20x field). Hepatocellular necrosis was scored using a scale based on 
the descriptors of severity used in the reporting of acute lobular hepatitis in human biopsies 
(0 – none; 1 – single cell necrosis; 2 – confluent necrosis; 3 – zonal necrosis; 4 – panacinar 
necrosis). The data are ordered categorical and therefore are presented as dotplots. 
 
Primary culture of mouse hepatic stellate cells. Livers from GKO, C57BL/6J controls, 
MFKO and control littermate mice were perfused with 5ml HBSS+, excised, cut into 2x2 
mm
2
 cubes and digested in HBSS medium supplemented with DNAse I, Collagenase IV and 
Pronase.  Released cells were purified through a 70µm strainer and separated by density 
gradient centrifugation in sequential concentrations of OptiPrep (Sigma Aldrich, Dorset, UK). 
1x10
6
 cells/well were plated and cultured in DMEM with 16% FBS, 1% 
penicillin/streptomycin. HSCs were left to spontaneously activate then were collected after 2, 
5, 8, or 11d in culture for mRNA and protein analysis. Pharmacological 11βHSD1 inhibition 
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was performed in primary cultures of C57Bl/6J HSCs. HSCs were treated with vehicle 
(DMSO), 500nM corticosterone, 500nM 11-dehydrocorticosterone and/or 10µM UE2316. 
HSC medium was replaced daily and all treatments were added daily with the medium 
change, for the duration of the experiment. Following 8d of treatment, HSCs were collected 
for mRNA and protein analysis.  
 
Other Standard Methods: Immunoblotting, RNA extraction, real time PCR, 11βHSD1 
activity assay and In situ hybridization have been described before (25,26,27) and detailed 
methods  can be found in Supporting Information.  
 
Statistical Analysis. All data are expressed as mean+/- SEM. Statistical analysis was 
performed using Graphpad prism or Statistica 7. 2-way ANOVA was used to test for the 
interaction of genotype/treatment analysis. 2-tailed unpaired Student’s t test or one-way 
ANOVA was used for the comparison of 2 (ie control versus KO mice) or 3 groups 
respectively (ie .control, CD, MCD diet comparisons).  
 
Results 
11βHSD1 expression is reduced during hepatic injury 
In the carbon tetrachloride (CCl4) murine model of liver fibrosis, whole liver 11βHSD1 
mRNA (Fig. 1A) and protein levels (Fig. 1B) were reduced during injury.  This injury-
associated reduction in whole liver 11βHSD1 mRNA, was recapitulated in both the  
thioacetamide (TAA) (Fig. 1C) model of liver fibrosis, and in the CDD and MCDD models 
of steatosis and NASH (Fig. 1D). 11βHSD1 activity levels were not significantly altered 
during peak CCl4-induced fibrosis (Supporting Fig. S1A). During the scar resolution phase 
following CCl4 injury, 11βHSD1 mRNA and protein levels returned to levels seen in 
uninjured (vehicle-treated) mice (Fig. 1A-B). 
 
11βHSD1 is expressed in hepatic stellate cells, attenuating their activation in vitro 
Although 11βHSD1 is highly expressed in hepatocytes, the key cells orchestrating 
fibrogenesis in parenchymal liver injury models are the hepatic stellate cells (HSCs). HSCs 
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are “spontaneously” activated in culture such that αSMA (a global marker of spontaneous 
HSC activation in vitro) protein levels are maximal at day 8 (Fig. 2A). Significant 11βHSD1 
expression was detectable in primary murine HSCs, with a striking reduction observed in 
11βHSD1 mRNA (Fig. 2B), protein (Fig. 2C) and activity (Fig. 2D) following spontaneous 
HSC activation (day 8) in vitro. Similarly, 11βHSD1 gene expression was present in the 
human LX-2 (28) HSC cell line, and was significantly reduced in response to activation with 
TGF-β, a classic pro-fibrogenic stimulus (Supporting Fig. S1B). 
To investigate the functional role of 11βHSD1 in HSC activation, primary HSCs were 
isolated from GKO (11βHSD1-deficient) mice and showed significantly higher Acta2 (Fig. 
2E) and Col1a1 (Fig. 2F) mRNA levels at day 8 compared to control HSCs. 
Consistent with this effect of 11βHSD1 being mediated by amplification of glucocorticoids, 
incubation of wild-type murine HSCs with either corticosterone or 11dehydro-corticosterone, 
the inert substrate for 11βHSD1, reduced Acta2 (Fig.3A) and Col1a1 (Fig.3B) mRNA levels. 
The effects of 11dehydro-corticosterone were abrogated by co-administration of the specific 
11βHSD1 inhibitor UE2316 (Fig. 3A, 3B). 
 
Global 11βHSD1 deficient mice show increased hepatic myofibroblast activation 
following CCl4 injury 
To investigate whether reducing 11βHSD1 (in GKO mice) in vivo enhances MFB/HSC 
activation and delays the resolution of scarring, we utilized the reversible CCl4 liver fibrosis 
model because the times of peak injury and maximal scar resolution have been previously 
well defined; time points were chosen to reflect the injury and resolution phases since 
collagen deposition is higher at 24h and resolving after 72h (3). After 12 weeks of CCl4 
treatment, GKO mice showed significantly higher picrosirius red staining (Fig. 4A) and 
collagen I deposition (Supporting Fig.S2A) at peak (24h) fibrosis.  Increased fibrogenesis in 
the absence of 11βHSD1 was supported by elevated liver mRNA levels of Col1a1 (Figure 
4B). In keeping with enhanced myofibroblast activation, Western blot analysis showed that 
αSMA protein levels were higher at 24h and stayed elevated at 8d in GKO mice (Supporting 
Fig.S2B).  Similarly, histological quantification of αSMA immunostaining showed that the 
GKO mice retained higher αSMA during the resolution phase (72h; Fig. 4A), although no 
histological difference was detected at peak fibrosis. In addition, Acta2 (αSMA) gene 
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expression remained higher in GKO mice during resolution (72h; Fig. 4C). To identify 
whether the observed alteration in myofibroblast phenotype was specific to HSCs, we stained 
for reelin (Fig. 4D), a known marker of HSCs (29). We did not detect any significant 
difference in the number of reelin positive cells at 72h, the critical point in which markers of 
fibrosis were elevated in the GKO mice. Hence, no definitive conclusion could be drawn on 
the origins of myofibroblasts in this model.  
 
GKO mice show similar hepatocellular damage after chronic or acute liver injury 
To assess whether the exaggerated pro-fibrotic response in GKO mice following chronic 
CCl4 was due to more severe hepatocyte injury, we performed a detailed histopathological 
evaluation. This showed similar NAS inflammation, hepatocellular necrosis and total injury 
scores in GKO and control mice (Supporting Fig.S3A-C). In fact, plasma ALT and AST 
levels were lower in GKO mice compared to control injured mice during peak fibrosis (Fig. 
4E-F). Plasma albumin levels were comparable between genotypes at peak injury 24h time 
point (control vs GKO: 25.40±2.12U/l vs 22.80±0.66U/l) and remained at similar levels 
throughout the resolution phases (data not shown). 
 
To further evaluate the effects of global 11βHSD1-deficiency on hepatocellular injury, a 
single dose of CCl4 was administered to induce acute liver injury. As in the chronic CCl4 
model, the GKO mice showed significantly lower plasma ALT, AST, ALP but similar 
albumin levels (Supporting Fig. S4A-D).  The single dose confirmed similar histopathology 
scores between genotypes (Supporting Fig. S5A-C). Quantification of hepatocyte necrotic 
cell area using PAS staining showed similar degrees of hepatocellular death in GKO and 
control mice (Supporting  Fig.S5D).  
 
GKO mice show similar hepatic macrophage or neutrophil numbers to control mice  in 
CCl4 injury 
Apart from HSCs, macrophages have been implicated in both promoting fibrosis and 
facilitating resolution, therefore we further assessed if global 11βHSD1 deletion affects 
hepatic macrophages and neutrophil numbers during injury and resolution phases. Neutrophil 
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numbers were similar between GKO and control livers at all time points (Fig. 5A-B). 
Macrophage numbers (Fig. 5A-C) and cytokine mRNA levels of Mcp1and Il1 (Fig. 5D-E) 
were also similar in GKO and control mice. Taken together these data suggest that enhanced 
pro-fibrotic response in GKO mice is not due to exacerbated inflammation or macrophage-
induced fibrosis but is more likely to reflect a direct effect on hepatic stellate cell activation 
pathways. 
 
Myofibroblast/Stellate cell 11βHSD1 knockdown enhances fibrosis markers in response 
to chronic CCl4.  
To distinguish between possible contributions of 11βHSD1 deficiency in MFB and 
hepatocytes to the pro-fibrotic phenotype, we generated 2 independent mouse models 
targeting 11βHSD1 in either hepatocytes or MFB/HSC. Mice with hepatocyte-specific 
deficiency in 11βHSD1 (LKO) showed almost complete (94-100% knock down) loss of 
11βHSD1 (Supporting Fig. S6A-B). At 24h after chronic CCl4 the LKO mice showed 
identical hepatic pro-fibrotic responses histologically (Fig. 6A), similar liver function test 
changes (Fig. 6B-C) and identical macrophage or  neutrophil numbers (Fig. 6D-E) to control 
littermates. Thus, deletion of 11βHSD1 in hepatocytes does not mimic the changes in liver 
fibrosis in GKO mice.  
 
To assess the specific role of 11βHSD1 in the regulation of MFB/HSCs in the CCl4 model, 
we used mice with MFB/HSC-specific 11βHSD1 knockdown (MFKD). HSCs isolated from 
MFKD mice, demonstrate a 50-60% reduction in 11βHSD1 expression in vitro (Supporting 
Fig. S6C-D) compared to littermate controls. Following chronic CCl4 administration, MFKD 
mice showed increased COL1 and αSMA immuno-staining (Fig.7A) and significantly higher 
Acta2 mRNA (Fig.7B) levels at 24h post CCl4 liver injury. No significant difference was 
detected in PSR staining (Fig.7A)  or plasma ALT/AST levels (Fig.7C-D) between genotypes. 
Enhanced myofibroblast activation in MFKD mice was also confirmed in ex-vivo primary 
HSCs from MFKD mice that showed significantly higher Acta2 and Col1a1 levels at days 2, 
5 and 8 in culture (Fig. 7E-F). 
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Pharmacological 11βHSD1 inhibition increases MFB activation and early fibrosis, but 
enhances scar resolution 
To address the clinical relevance of our findings for 11βHSD1 inhibitor therapies, and 
specifically test the potential intervention times (prophylactic/injury/repair) we used the 
11βHSD1 inhibitor UE2316 in the CCl4 liver fibrosis model (Fig. 7A). During CCl4 
administration, UE2316-treated animals had slightly lower body weights (Supporting Fig. 
S7A), as shown before (21), but no difference in liver-to-body weight ratio (Supporting Fig. 
S7B). Overall, as observed in GKO mice, UE2316 treatment throughout the period of CCl4 
administration exacerbated hepatic fibrosis measured 24h following termination of CCl4, as 
shown by PSR staining (Fig. 7B) and collagen 1 (Fig. 7B) immunohistochemistry. UE2316 
treatment throughout CCl4 injury also inhibited later scar resolution, as shown by elevated 
PSR and collagen 1 up to 8 days post-CCl4. The UE2316 treated group had higher αSMA as 
early as 6 hours after the last CCl4 injection, but this normalized during later resolution (Fig. 
7D). Furthermore, as seen in GKO mice, plasma ALT and AST levels were significantly 
lower at both peak injury (24 h) and late resolution (day 8) in the UE2316 group compared to 
vehicle (Fig. 7E-F).  
 
In order to investigate the therapeutic potential of 11βHSD1 inhibition and/or dissect the 
effects on injury/repair  phases we administered UE2316 only during scar resolution, i.e. 
commencing UE2316 48h following the final CCl4 injection (Fig.7A).There was no 
significant difference in total collagen or collagen 1 deposition in the UE-R group (Fig. 7B-C) 
compared to vehicle control, but  administering UE2316 during the resolution phase 
accelerated the reduction in the number of αSMA positive cells (Fig.7D) and reduced plasma 
ALT levels (Fig.7E) at day 8. 
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Discussion 
Collectively, these data from a comprehensive series of liver fibrosis studies using mice with 
either global or myofibroblast-restricted 11βHSD1-deficiency, a translational study using a 
small molecule 11βHSD1 inhibitor and our in vitro work using primary HSCs, demonstrate 
that attenuation of 11βHSD1 activity within the hepatic myofibroblast population enhances a 
profibrogenic myofibroblast phenotype and promotes liver fibrogenesis.  The profibrotic 
response most likely occurs in HSCs, and not in hepatocytes (LKO had no phenotype), and is 
mediated by suppression of glucocorticoid action via 11βHSD1inhibition. It is also evident 
that in all the models of liver injury that we assessed, 11βHSD1 is suppressed during injury. 
Therefore, administration of systemic 11βHSD1 inhibitors, drugs which are currently under 
investigation in Phase 2 clinical trials, to patient groups at risk of NAFLD or NASH, may 
have unpredictable adverse effects on liver fibrosis progression and regression.  
The profibrotic responses in the GKO and pharmacological inhibition are not due to greater 
hepatocellular injury since histopathology and necrosis scores did not show marked 
differences in liver damage. Interestingly, biochemical markers of hepatocyte death – ALT 
and AST were reduced in 11βHSD1 global deficiency/inhibition. The lower ALT/AST at 
peak fibrosis in our study is currently unexplained. However, given the role of 11βHSD1 in 
the modulation of anti-inflammatory glucocorticoids, we speculate that this could relate to 
differential effects of reduced GC exposure (systemically versus locally).  Indeed, 
administration of exogenous GC to patients has been shown to increase ALT and AST levels 
(30). Animal studies have also shown that GCs increase ALT activity (31,32), therefore 
reduced GC availability with 11βHSD1pharmacological inhibition/global genetic deficiency 
could explain the reduced ALT/AST. In the cell type (LKO, MFKD)-specific models, the 
ALT/AST levels were similar to littermate controls. Hence, ALT/AST levels may not always 
reflect the degree of hepatocellular damage and histological confirmation of changes should 
be sought where possible.  Note that the ALT and AST levels differed in the respective 
control strains likely because of background stain and age differences; this does not change 
the interpretation of our data.   
  
Hepatocyte-specific deletion of 11βHSD1 did not show any apparent effect on liver fibrosis 
or hepatic injury in the CCl4 injury model, ruling out hepatocytes as a key locus for 
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11βHSD1 in this context. Similarly in a fatty liver model, LKO mice failed to show 
significant metabolic abnormalities or a distinct phenotype from control littermates (33). It is 
possible that in global deficiency, compensatory hypothalamic-pituitary-adrenal (HPA) axis 
activation (due to increased GC clearance) or paracrine modulators could affect pro-fibrotic 
responses. For example, global 11βHSD1 deficiency or inhibition, but not hepatocyte-
specific deficiency (33,34), leads to moderate weight loss, which may modulate injury 
responses in the liver by altered leptin signalling (35). This suggests that 11βHSD1 
deficiency either in other organs, or in other cells within the liver, is important to modifying 
the injury response. 
 
Our data using the MFKD mouse model and ex-vivo HSC data (from MFKD, GKO, UE2316) 
suggest that 11βHSD1 could be a key regulator of MFB/HSC function. Reduction of 
11βHSD1 in MFB/HSC populations is permissive towards a profibrotic profile with 
increased collagen-1 (a GC target gene) and α-smooth muscle actin levels. The lack of a 
significant difference in PSR staining in the MFKD model could be due to residual levels 
(50-60% knock down) of 11βHSD1 in MFB/HSC. The inhibitory effects of glucocorticoids 
on pro-fibrotic genes have also been observed in other disease models where fibroblasts play 
a key role. For example, in TGFβ-stimulated human lung fibroblasts, glucocorticoid 
treatment significantly reduced extracellular matrix related genes (36). Glucocorticoids also 
inhibit the pro-inflammatory cytokine-induced proliferation of adult rat cardiac fibroblasts 
(37). In support of our data, dexamethasone treatment of HSCs resulted in a significant 
reduction of Tgf-β-Smad mediated signalling (38), the upstream regulator of matrix 
deposition by activated HSCs. Although the effects of MFKD, 11βHSD1 genetic deficiency 
and pharmacological inhibition suggest direct activation of HSCs in vitro and the fact that 
HSCs are the major source of myofibroblasts in hepatotoxic liver injury (CCl4) (39,40), it is 
possible that other hepatic myofibroblast subpopulations could have contributed to the effects 
observed in our in vivo studies.  
 
Hepatic inflammation is also closely linked to liver fibrosis. Liver macrophages are critical 
regulators of both fibrogenesis and scar resolution (3, 41). Glucocorticoids are well known 
for their anti-inflammatory properties, and 11βHSD1 is expressed in macrophages and other 
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inflammatory cells (42). Effects of 11βHSD1 on inflammation are highly context-dependent.  
For example, GKO mice show reduced inflammation in atheroma lesions and decreased 
MCP1 expression and macrophage numbers in adipose tissue (16) after high fat feeding, but 
enhanced responses in serum arthritis and chemically induced peritonitis and pleurisy (42), 
increased serum TNF-alpha and IL-6 levels when challenged with LPS (43) and enhanced 
hepatic inflammation in a NAFLD-diet inducing model (44). We suspected that the pro-
fibrotic profile seen in GKO and UE2316 treated mice could be attributed to exaggerated 
inflammatory response to CCl4. However, we did not find any elevation of key inflammatory 
markers or in either hepatic macrophage or neutrophil numbers. Therefore, in our model it is 
unlikely that 11βHSD1 deficiency plays a regulatory role on inflammatory cell function.  
 
We have not excluded other mechanisms potentially affecting fibrosis. In contrast with 
permissive effects on liver fibrosis in CCl4 injury, GKO mice showed protection from adipose 
tissue scarring after high fat feeding. This anti-fibrotic role is associated with enhanced 
angiogenesis and reduced hypoxia in the adipose tissue of GKO mice (17), consistent with 
their enhanced angiogenesis in models of ischemic or injured tissue (15,18, 45). In chronic 
liver disease several studies show that angiogenesis is key in fibrosis progression, with 
exaggerated pathological angiogenesis leading to enhanced fibrosis (46-49) .Therefore 
increased angiogenesis with reduced 11βHSD1 in the liver could contribute to the enhanced 
fibrosis we observed. 
 
Our work for the first time provides insights of translational importance in the use of 
11βHSD1 inhibitors in liver injury. Administration of UE2316 prior to injury recapitulates 
the profibrotic phenotype seen in the GKO and MFKD genetic models. UE2316 restricted to 
the recovery phase, after chronic injury had been stopped, seemed to modestly reduce 
markers of myofibroblast activation. This dichotomous function of 11βHSD1 during injury 
and resolution, suggests context-dependent treatment effects. Similar paradigms for other 
pathways are now becoming more evident in the literature. For example, a recent study 
using VEGF-neutralizing antibodies showed 2 opposing effects:  prevented development of 
fibrosis but also disrupted hepatic fibrosis resolution and tissue repair.  During fibrosis 
resolution, VEGF inhibition impaired liver sinusoidal permeability, which was associated 
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with reduced monocyte infiltration of fibrotic liver and delayed tissue repair (50). GCs have 
known angiostatic mechanisms and we have previously shown that 11βHSD1 inhibition 
enhances VEGF expression which might be necessary during ECM remodelling at the scar 
resolution phase.     
 
Selective 11βHSD1 inhibitors have been tested in phase II trials of obese patients with type 2 
diabetes, but the modest size of their effects on glycemic control have stalled their 
commercial progress, and led to consideration of alternative/added indications, including 
NAFLD (13). From these preclinical data we cannot predict the consequences of 11βHSD1 
inhibition for liver injury, and this requires more careful investigation. From a therapeutic 
point of view, it appears that administration of 11βHSD1 inhibitors prior to injury (as a 
prophylactic measure) might reduce transaminases levels but will perhaps be permissive 
towards fibrosis and delay collagen degradation. In contrast, if it were possible to administer 
11βHSD1 inhibitors specifically during scar resolution, this may assist extracellular matrix 
remodelling.      
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Figure legends 
Fig.1: Reduced 11βHSD1 expression in mouse models of liver fibrosis. Hepatic 
11βHSD1mRNA levels measured by real time PCR (A) and protein levels (B), with upper 
panel showing representative immunoblot for 11βHSD1and GAPDH and lower panel 
quantification graph,  during peak (48h) and resolution (1week, 1month) phases in the 
reversible CCl4 (A,B) and TAA (C) liver fibrosis models, n=6/group.  (D)  Hepatic Hsd11b1 
mRNA levels in control (Con) diet, choline-deficient (CDD) and methionine-deficient 
(MCDD) NASH models, assessed by in situ mRNA hybridization (quantification graph 
showing average grain counts per area) n=6/group* p<0.05; ** p<0.01; *** p<0.001 
compared to the vehicle group (A-C). 
+
p<0.05, 
+++
p<0.001 compared to the 48 hour injury 
time point. 
Fig.2: Reduced 11βHSD1 expression during HSC activation in vitro.  Expression levels of 
11βHSD1 and α-SMA during ex-vivo wild type mouse HSC activation in vitro (n=3/group). 
(A) α-SMA protein, (B) Hsd11b1 mRNA, (C) 11βHSD1 protein and  (D) 11βHSD1 
enzymatic activity (% conversion  11-dehydrocorticosterone to corticosterone) were 
measured during 2-11 days post activation. Comparison of  Acta2  (E) and Col1a1 (F) mRNA 
levels in wild type (white bars)  and GKO (black bars) HSCs during 2-11days post activation. 
* p<0.05; ** p<0.01; *** p<0.001 * compared to basal day 2 (A-D) or between genotypes 
within a time point (E-F); 
+++
p<0.001 comparisons between day 5 and 8 (D). 
Fig.3: Glucocorticoid inhibition of profibrotic gene expression is amplified by 11βHSD1 
in murine HSCs in vitro. mRNA levels of Acta2 (A) and Col1α1 (B) in C57Bl6/J HSCs in 
primary culture for 8 days  and treated with combinations of vehicle ( white bars), 500nM 11-
dehydrocorticosterone (compound ‘A’, vertical stripped bars), 500nM corticosterone 
(compound ‘B’, horizontal stripped bars),  10µM UE2316 (compound ‘U’; grey bars ), and 
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combination of A+B (black bars). Levels of mRNAs  of interest are expressed relative to 18S 
RNA. Experiments were conducted in triplicate: * p<0.05; ** p<0.01. 
Fig.4:  Increased fibrotic response in livers of global 11βHSD1-deficient (GKO) mice 
after CCl4 administration. GKO (black bars) and wild type (white bars) mice were 
administered twice weekly ip injections of CCl4 for 12 weeks. 24h time point represents the 
peak injury and 72h-8d is the scar resolution phase. (A) Representative images of total 
collagen (picrosirius red, PSR), and smooth muscle actin (αSMA) staining during injury 
(24h) and resolution (72h and 8 days) phases, with arrowheads pointing to intense collagen 
staining and smooth muscle actin positive cells in control and GKO mice. Quantification of 
staining for PSR and αSMA are shown below the corresponding panel of representative 
images. Pixels of 30-40 continuous fields (x80) from each section were randomly selected 
and measured.  Hepatic levels of Col1a1 (B), and   Acta2 mRNA (C) were measured by 
qPCR and normalized for 18S.  (D) Representative images (scale bar 100µm) and 
quantification graph of reelin immunohistochemistry (at 72h) to identify hepatic stellate cells. 
Plasma levels of alanine (ALT; E) and aspartate (AST; F) aminotransferases during injury 
and resolution phases. N=5-6 in each group; * p<0.05; ** p<0.01; *** p<0.001 between 
genotypes within time points. 
Fig. 5: Similar inflammatory responses to control mice in GKO following CCl4 liver 
injury. (A) A panel of representative flow cytometry images gating for Ly6G
+
 CD11b
+ 
cells 
(neutrophils) and  F4/80
+
 CD11b
 +
 cells (macrophages) with quantification graphs (at the 
bottom of each representative image panel) for inflammatory cells as % of  neutrophils and 
macrophages among all non-parenchymal cells in the liver. Hepatic levels of mRNAs 
encoding MCP-1 (B) and IL-1beta (C) quantified by qPCR and normalized for 18S in control 
(white bars) and GKO mice (black bars). There were no differences between groups 
(n=6/group).  
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Fig.6: Mice with hepatocyte-specific 11βHSD1-deficiency (LKO) and their littermate 
controls show similar hepatic responses to CCl4 injury. (A) Representative images of total 
collagen (picrosirius red, PSR), collagen 1 (Col1) and α-smooth muscle actin (αSMA) 
staining at 24h peak injury in control and LKO mice with quantification graphs at the bottom 
of each representative image panel. Plasma levels of ALT (B) and AST (C) in control 
(Hsd11b1
fl/fl
 ; white bars) and LKO (black bars) mice during injury. There were no 
differences between groups (n=6/group). Control (white bars) and LKO (black bars) liver 
sections were stained for neutrophils GR-1 (Ly6G) (D) and macrophages (F4/80) (E).  20-30 
consecutive fields with magnification *400 were quantified for each section. Cell number of 
each field was counted by an investigator, who was blinded for the genotype and treatment of 
the section. The average of cell number per field was calculated.   There were no differences 
between groups (n=5-6/group).  
 
Fig.7: Knock-down of 11βHSD1 specifically in HSC/MF populations (MFKD) enhances 
hepatic myofibroblast activation and fibrotic response in CCl4 injury. Male mice (10-12 
weeks old) were administered CCl4 i.p. for 12 weeks to induce liver injury (n=6/group). (A) 
Representative images of total collagen (picrosirius red, PSR), collagen 1 (Col1) and α-
smooth muscle actin (αSMA) staining at 24h peak injury in control and MFKD  mice with 
quantification graphs at the bottom of each representative image panel.(B) Hepatic Acta2 
mRNA levels were measured by qPCR and normalized for 18S. Plasma levels of ALT (C) 
and AST (D) in control (Hsd11b1
fl/fl
 ; white bars) and MFKD (black bars) mice during injury.  
HSCs were isolated from 8 week old mice. Acta2  (E) and Col1a1 (F) mRNA levels were 
measured  during 2-5-8 days post  ex-vivo HSC activation in MFKD (black bars) and control 
littermates (white bars) (n=3/group). * p<0.05; ** p<0.01; *** p<0.001 comparisons between 
genotypes. 
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Fig.8: Inhibition of 11βHSD1 in mice enhances the early liver fibrotic response to CCl4 
but when restricted to the repair phase, improves resolution of scarring. (A) Schematic 
view of the experimental design. Mice were administered twice weekly ip injections of CCl4 
for 12 weeks, and divided into 3 groups: a Chow diet (CD; white) group that was kept on 
vehicle diet for the duration of the experiment; a UE group (grey) that was kept on a diet 
containing the 11βHSD1 inhibitor UE2316 for the whole duration of the experiment; and a 
UE-R group (black) that started on a vehicle chow diet and switched to the UE diet 48h after 
the last CCL4 injection. In this experiment a very early 6h time point was included to capture 
the earliest injury response. Representative images and quantification graphs of PSR (B), 
Col1 (C) and αSMA (D) staining were quantified in 30-40 continuous fields (x80) from each 
section of each group. Plasma levels of ALT (E) and AST (F) in mice treated with vehicle 
(white bars), UE (grey bars) or UE-R (black bars).  N=5-6 in each group; * p<0.05; ** 
p<0.01; *** p<0.001 tested by two-way ANOVA.  
Supporting Fig.S1:  11βHSD1 levels in CCl4 liver injury and in human HSCs in culture.  
(A) 11βHSD1 activity in liver homogenates from the CCl4 injury model (n=6/group) after 
vehicle or after 48 hours or 1 week of CCl4 administration.  (B) Hsd11b1 mRNA levels were 
measured in human LX-2 HSC incubated in serum-free medium (n=3 replicates per 
treatment) and treated with vehicle or activated with TGF-β (2ng/ml) for 16h. * p<0.05 tested 
by one-way ANOVA (A) or T-test (B). 
Supporting Fig.S2: Higher hepatic collagen 1 and αSMA protein levels in GKO in the 
CCl4 injury model.  . (A) Representative images and quantification graph of collagen 1 
staining during injury (24h) and resolution (72h and 8 days) phases, with arrowheads pointing 
to intense collagen 1 staining in control (white bars)  and GKO (black bars) mice.  (B) 
Representative hepatic α-SMA western blot image and quantification  graph in control and 
GKO mice at peak (24h) and resolution (72h, 8d) time points in the CCl4 liver fibrosis model, 
n=6/group.  * p<0.05; ** p<0.01 between groups tested by two-way ANOVA. 
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Supporting Fig.S3: Similar histopathology scores in GKO and control mice in chronic 
CCl4 injury model. GKO (black circles) and control  (open circles) liver H&E stained 
sections from the 24h peak fibrosis time point were scored  for (A) NAS inflammation (insert 
table showing the scoring system) (B) hepatocellular necrosis (insert table showing the 
scoring system) and (C) total liver injury was calculated  by adding the scores from A and B. 
n=6/group. There was no ballooning or steatosis or Mallory bodies observed.  
Supporting Fig.S4: GKO mice show lower plasma transaminases after acute single dose 
CCl4 injury compared to control mice. Plasma levels of alanine (ALT; A), aspartate (AST; 
B) aminotransferases and alkaline phosphatase (ALP;  C) and albumin (D). n=6/group; * 
p<0.05; ** p<0.01 between genotypes tested with Student’s t test. 
Supporting Fig.S5: GKO mice have similar hepatocellular damage and necrotic areas  
after single dose CCL4 injury compared to control mice. GKO (black circles) and control  
(open circles) liver H&E stained sections from a single CCl4 dose  were scored  for (A) NAS 
inflammation  (B) hepatocellular necrosis  and (C) total liver injury was calculated  by adding 
the scores from A and B. n=6/group. There was no ballooning or steatosis or Mallory bodies 
observed. (D)Representative images  (scale bar 200µm) and quantification graph of  Periodic 
acid-Schiff  (PAS) stain in livers of  control (white bars) and GKO mice (black bars). Pale 
blue stain indicates necrotic areas.   
Supporting Fig.S6: Recombination efficiency in LKO and MFKD mouse models.(A) 
Hepatic Hsd11b1 mRNA normalized for 18S and (B) 11β-HSD1 protein normalized for 
GAPDH in LKO mice shows almost complete 11β-HSD1 ablation  compared to control (Cre-
) littermates (n=6/group). *** p<0.001 between groups tested with Student’s t-test. (C) 
Hsd11b1 mRNA normalized for 18S in isolated HSCs from MFKD (black bars)and control 
littermates ( white bars) during 2-5-8 days post  ex-vivo HSC activation (n=3/group). For 
clarity only significant differences ** p<0.01; *** p<0.001 * between genotypes within a 
time point are shown. Note that as seen if Fig. 2B Hsd11b1 mRNA is reduced during HSC 
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activation in control mice. (D) 11βHSD1 enzymatic activity (% conversion  11-
dehydrocorticosterone to corticosterone) was measured  at day 8 post HSC activation 
(n=5/group).      
Supporting Fig.S7: Body and liver weights after UE2316 inhibitor administration.  (A) 
body weight (BW) comparisons between chow diet (open circle) and UE2316  (black square) 
groups  during the 12 week CCl4 injury model (B) liver weights corrected for BW between 
chow diet (white bars) and UE2316 (grey bars) and UE-R (black bars) groups during the 12 
week CCl4 injury model. Repeated measures ANOVA, ** p<0.01;  *** p<0.001 significant 
differences between groups. 
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Reduced 11βHSD1 expression during HSC activation in vitro.    
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Glucocorticoid inhibition of profibrotic gene expression is amplified by 11βHSD1 in murine HSCs in vitro  
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GKO mice have similar macrophage and neutrophil numbers to control mice after  CCl4 injury  
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LKO mice show no apparent phenotype in CCl4 injury  
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